Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evalve has reported positive results from Everest trial, which showed that percutaneous mitral repair using the MitraClip device may successfully reduce mitral regurgitation in patients suffering from functional mitral regurgitation over a two-year period.
Subscribe to our email newsletter
The Everest trial is evaluating the safety and efficacy of the MitraClip device for the treatment of mitral regurgitation (MR). The data analysis was based on 23 patients with moderate-to-severe or severe functional MR (FMR). The data shows that 83% of the 23 FMR patients had successful MR reduction after the MitraClip procedure. Additionally, the majority (74%) of successfully treated FMR patients showed MR reduction to less than or equal to 2+ MR. Importantly, the MR reduction was maintained, with a Kaplan-Meier durability of MR reduction in 89% of patients at one and two years.
Other results, showed that at one year, clinical symptoms improved or stabilized compared to baseline in 92% of successfully treated FMR patients (matched data, n=12). Symptomatic relief was seen in 70% of FMR patients who had a history of heart failure.
Ferolyn Powell, president and CEO of Evalve, said: “The reduction of MR with durable results and improved heart function highlight the potential of the MitraClip device. We believe we are making strides with a new, less-invasive method of valve repair for both functional MR and degenerative MR patients.”